Section Arrow
LEGN.NASDAQ
- Legend Biotech Corp
Quotes are at least 15-min delayed:2025/09/04 01:24 EDT
Regular Hours
Last
 35.95
+1.73 (+5.06%)
Day High 
36.17 
Prev. Close
34.22 
1-M High
39.16 
Volume 
1.11M 
Bid
35.6
Ask
36.09
Day Low
34.1444 
Open
34.2 
1-M Low
34.15 
Market Cap 
6.32B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 35.1 
20-SMA 36.22 
50-SMA 37.77 
52-W High 57.94 
52-W Low 27.34 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.78/1.35
Enterprise Value
6.66B
Balance Sheet
Book Value Per Share
5.61
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
627.24M
Operating Revenue Per Share
0.89
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences0.4574-0.0792-14.76%6.98PE
ADAPAdaptimmune Therapeutics plc0.0526-0.0052-9.00%-- 
CARMCarisma Therapeutics0.3699-0.0701-15.93%-- 
ETHZETHZilla Corporation2.52-0.15-5.62%-- 
STTKShattuck Labs1.28+0.27+26.73%-- 
Quotes are at least 15-min delayed:2025/09/04 01:24 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.